The above GO enrichments highlight lipid metabolism, immunity, and synaptic function, the same processes that encompass AD risk genes: lipid metabolism (APOE, CLU, ABCA7, ECHDC3), immune response (TREM2, CR1, MS4A, CD33, EPHA1, C4b, H2-Eb1/2, SCIMP, INPP5d), and synaptic function (PICALM, CD2AP, BIN1, CNTNAP2)16–18. This evidence concerns the gene EPHA1 and Alzheimer disease.